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Introduction {#sec1}
============

Under inflammatory conditions, immature myeloid cells expand, leave the bone marrow, and travel to the site of injury where they may accumulate and/or differentiate. Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells representing an alternative differentiation pathway of myeloid cell development during inflammation or stress that have potent immunosuppressive roles including the suppression of antigen-specific and non-antigen-specific T cell function ([@bib24]).

In humans, MDSCs are defined as being HLA-DR^-/low^CD33^+^CD11b^+^ and can be further subdivided into granulocytic (expressing CD15^+^, but CD14^-^) or monocytic (expressing CD14^+^). In intracellular bacterial infection in humans, MDSCs have been isolated from patients with tuberculosis and are shown to inhibit CD4^+^ T cell responses and CD8^+^ T cell proliferation by reducing cytokine responses ([@bib5]).

Leprosy is caused by the intracellular bacterium *Mycobacterium leprae* (mLEP) and presents as a spectrum in which the clinical manifestations correlate with the immune response to the pathogen. On one end of the spectrum, tuberculoid leprosy (T-lep) is a self-limited infection with the presence of few if any bacilli and involves predominantly a Th1 response. Lepromatous leprosy (L-lep) is the progressive form of the disease characterized by a high bacillary load within macrophages and a Th2 type response ([@bib33]). Less is known about the reactional states that often occur in patients with leprosy. Reactional states provide a window into immunopathology of the disease and occur when a patient\'s immune status rapidly changes resulting in tissue injury, including nerve damage. Type 1 reactions, or reversal reactions (RRs), are associated with an increase in cell-mediated immunity to *M*. *leprae* with reduction in viable *M*. *leprae*, representing a switch from a disseminated/progressive form to a self-limited form of disease. In RR, edema within granulomas and nerves is prominent and the myeloid cells include monocytes, macrophages, and multinucleated giant cells ([@bib37]). Type 2 reactions, also known as erythema nodosum leprosum (ENL), are characterized by the appearance of skin nodules due to immune complex formation and IL-1β release, occurring in patients with L-lep leading to tissue injury without a reduction in viable bacilli ([@bib13], [@bib16], [@bib45]). In ENL reactions, neutrophils are prominent and may be accompanied by vasculitis, suggesting the presence of immune complex disease ([@bib1], [@bib16], [@bib20], [@bib43]). What role, if any, MDSCs play in leprosy has not been investigated. Since MDSCs are associated with chronic immunosuppressive states and nosocomial infections in sepsis/septic shock ([@bib21]), we hypothesized that MDSCs may also participate in the pathogenesis seen in patients with leprosy.

Results {#sec2}
=======

Cells with an MDSC Phenotype Are Expanded in the Blood and Skin of Patients with Reactional Leprosy {#sec2.1}
---------------------------------------------------------------------------------------------------

We investigated the frequency of human granulocytic MDSC in patients with leprosy, defined as HLA-DR^-^CD33^+^CD11b^+^CD15^+^ ([@bib24]). Using flow cytometry, we identified the expansion of a population of myeloid cells in the blood of patients with leprosy with increased side scatter properties present only at low levels in healthy control patients ([Figure S1](#mmc1){ref-type="supplementary-material"}). These cells expressed cell surface markers typically expressed by MDSCs (HLA-DR^-^CD33^+^CD15^+^) and were enriched in patients with ENL, RR, and L-lep ([Figure 1](#fig1){ref-type="fig"}A). The frequency of HLA-DR^-^CD33^+^CD15^+^ cells was greater in patients with active versus inactive RR and ENL reactions. In contrast, patients with T-lep along with healthy controls had the lowest levels of HLA-DR^-^CD33^+^CD15^+^ cells ([Figure 1](#fig1){ref-type="fig"}A). Patients were considered to have active disease if they were undergoing an active immune response. Patients were inactive if they have completed treatment or were weaning off treatment. HLA-DR^-^CD33^+^CD15^+^ cells in patients with leprosy were of the granulocytic subpopulation ([@bib3]), expressing CD15 but not CD14 ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1MDSCs Are Increased in Blood and Lesional Skin of Patients with Leprosy(A) Dot graph depicting the percentage of HLA-DR^-^CD33^+^CD15^+^ cells in the peripheral blood of patients with leprosy (ENL \[red circles, active\] n = 9, ENL \[black circles, inactive\] n = 15, RR \[red triangles, active\] n = 8, RR \[black triangles, inactive\] n = 8, L-lep n = 7, T-lep n = 3, Healthy Control \[HC\] n = 24; line represents mean of all samples. Kruskal-Wallis p \< 0.0001; Dunn\'s post hoc analysis ∗∗∗∗p \< 0.0001).(B and C) (B) Confocal microscopy---representative confocal image depicting HLA-DR^-^CD33^+^CD15^+^ cells (pointed out by white arrows) in a representative ENL lesion (63X, one labeled representative section of at least three per group) and (C) representative flow cytometry plot of RR fresh skin lesion biopsy (left two panels) and dot plot from ENL (n = 2) and RR (n = 3) patient biopsies (right panel) reveal the presence of HLA-DR^-^CD33^+^CD15^+^ cells in lesions of patients with reactional leprosy.(D) Model of suppression assay.(E and F) (E) ^3^H incorporation at 72 h. Left panel depicts T cell proliferation in response to mLEP sonicate in the absence of MDSCs or MDSC-like cells (n = 22, average of all samples); right panel depicts Proliferation Index (T cell proliferation \[CPM\] without MDSC/T cell proliferation \[CPM\] with MDSC). Addition of ENL but not RR or HC MDSC at a ratio of 10:1 and 1:1 (MDSC to APC) results in suppression of Tcell proliferation (ENL \[black circles, inactive\] n = 3, ENL \[red circles, active\] n = 4, L-lep \[gray circles\] n = 2, RR \[black triangles, inactive\] n = 5, RR \[red triangles, active\] n = 2, T-lep \[gray triangle\] n = 1, and HC \[open squares\] n = 5; line represents mean ± SEM of all samples). One-way ANOVA p \< 0.0001; Tukey\'s post hoc analysis, ∗p \< 0.05, ∗∗p \< 0.01, ŦŦ,∗∗p \< 0.01, ŦŦŦ,∗∗∗p \< 0.001 compared with healthy controls (∗); compared with RR (Ŧ). and (F) IFN-γ production at 24 h. Left panel depicts IFN-γ production in response to mLEP sonicate in the absence of MDSCs or MDSC-like cells (n = 13, average of all samples); right panel, IFN-γ production index (T cell IFN-γ production without MDSC/T cell IFN-γ production with MDSC) at 24 h (ENL \[active and inactive, circles\] n = 4, RR \[active and inactive, triangles\] n = 4 and HC \[open squares\] n = 5; line represents mean ± SEM of all samples). One-way ANOVA p = 0.0011; Tukey\'s post hoc analysis ∗p \< 0.05 compared with healthy controls (∗); compared with RR (Ŧ).

MDSCs are readily identified in circulation, whereas their presence in tissue indicates local immune regulation at the site of infection as a part of disease pathogenesis ([@bib8], [@bib28]). We next investigated whether cells with an MDSC phenotype (HLA-DR^-^CD33^+^CD15^+^) are present in the skin of patients with leprosy. By immunofluorescence of frozen biopsy specimens and flow cytometry of fresh biopsy specimens, we detected HLA-DR^-^CD33^+^CD15^+^ cells in lesions of patients with RR and ENL ([Figures 1](#fig1){ref-type="fig"}B and 1C). The presence of MDSC in leprosy lesions suggests the potential immunomodulatory role at the site of disease.

MDSCs from Patients with Leprosy Suppress *M*. *leprae*-Specific T Cells {#sec2.2}
------------------------------------------------------------------------

A key characteristic of MDSCs is the ability to suppress the function of immune effector cells. We therefore assessed whether the cells possessing the MDSC phenotype suppressed the function of T cells, measuring their ability to inhibit proliferation and IFN-γ response of an *M*. *leprae*-specific T cell clone. We performed functional experiments using HLA-DR^-^CD33^+^ enriched cells isolated from peripheral blood. These cells were also CD15^+^ but were only selected based on HLA-DR^-^CD33^+^. Following incubation of antigen-presenting cells (APCs) with *M*. *leprae* sonicate for 1 h, an equal number of *M*. *leprae*-specific T cells are added to assess their antigen-specific proliferation. To measure the impact of MDSCs on T cell activity, a T cell suppression assay was performed. Patient HLA-DR^-^CD33^+^ cells were added to T cells primed with antigen-presenting cells pulsed with antigen to assess the effects of HLA-DR^-^CD33^+^ on T cell proliferation and production of IFN-γ ([Figures 1](#fig1){ref-type="fig"}C--1F). Although every group of patients possessed HLA-DR^-^CD33^+^ cells that did not possess significant suppressive activity (\>30% suppression), only HLA-DR^-^CD33^+^ cells isolated from patients with ENL (active or inactive) and L-lep suppressed T cell proliferation and IFN-γ production from the majority of patients ([Figures 1](#fig1){ref-type="fig"}E and 1F). These data indicate that HLA-DR^-^CD33^+^ cells from patients with L-lep, with or without ENL, are MDSCs with the capacity to suppress antigen-specific T cell responses. The HLA-DR^-^CD33^+^ cells from patients with RR and T-lep are MDSC-like cells, displaying the same phenotype of MDSC by flow cytometry but not suppressing adaptive immune function. Furthermore, these data suggest that leprosy serves as a model to test the functional plasticity of HLA-DR^-^CD33^+^ cells since infection with the same organism can elicit differential function of cells expressing the MDSC phenotype.

Endoplasmic Reticulum Stress Is Activated in MDSCs from Patients with ENL {#sec2.3}
-------------------------------------------------------------------------

To better understand why cells with the same surface phenotype isolated from patients with different clinical manifestations vary in their suppressive activity, we performed RNA sequencing (RNA-seq) from isolated HLA-DR^-^CD33^+^ cells from patients with suppressive activity, ENL, and from patients who did not possess suppressive activity, RR, and performed differential expression gene analysis (ENL n = 4, RR n = 5, HC n = 3). We chose to focus our RNA-seq studies on patients with ENL and RR since these patients displayed the largest expansion of these cells. We found that 46 genes were increased 2-fold or more in ENL MDSC, with an adjusted p value of \<0.05, when compared with RR MDSC, whereas only seven genes were increased 1.8-fold or more in RR MDSC compared with ENL MDSC. Shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} are the top 10 most differentially expressed genes in MDSC from patients with ENL when compared with patients with RR and the top seven most differentially expressed genes in RR MDSC-like cells compared with ENL MDSC. Of note, one of the most overexpressed genes in ENL MDSC compared with RR MDSC was lectin type oxidized lipid receptor 1 (OLR1), a gene shown to be expressed in granulocytic (PMN)-MDSC with immunosuppressive function when compared with neutrophils of healthy people or patients with cancer who did not possess immunosuppressive function ([@bib3]).Table 1Top 10 Genes Upregulated in ENL MDSC over RR MDSC-like CellsLog~2~Fold Changep Valuep-AdjGene Name−4.24391.17 × 10^−4^0.0374OSR2Odd-skipped related 2−3.78391.66 × 10^−4^0.0472CCL20Chemokine (C-C motif) ligand 20−3.60297.55 × 10^−5^0.0289IL24Interleukin-24−3.35882.3 × 10^−6^0.0020LIFLeukemia inhibitory factor−3.30487.28 × 10^−6^0.0047OLR1Oxidized low-density lipoprotein (lectin-like) receptor 1−3.06361.06 × 10^−6^0.0010HES1Hairy and enhancer of split 1−3.05294.29 × 10^−7^0.0005PHLDA1Pleckstrin homology-like domain, family A, member 1−2.93232.01 × 10^−7^0.0003RGCCRegulator of cell cycle, response gene to complement 32 protein−2.03391.65 × 10^−10^0.000IL1BInterleukin 1 beta−2.91371.06 × 10^−5^0.0062PGLYRP1Peptidoglycan recognition protein 1Table 2Top 7 Genes Upregulated in RR MDSC-like Cells over ENL MDSCsLog~2~Fold Changep Valuep-AdjGene Name2.993561.70 × 10^−4^0.0472PRICKLE1Prickle homolog 12.269796.47 × 10^−8^0.0001AIM2Absent in melanoma 21.634215.87 × 10^−5^0.0243GBP4Guanylate binding protein 41.423522.38 × 10^−5^0.0115FCGR2CFc fragment of IgG, low affinity llc, receptor for (CD32)1.097381.10 × 10^−4^0.0356SRBD1S1 RNA binding domain 10.88411.10 × 10^−4^0.0356APOL3Adolipoprotein L, 30.870081.70 × 10^−5^0.008KIAA0922Transmembrane protein 131-like (hg19 protein)

Since OLR1 was associated with endoplasmic reticulum (ER) stress in MDSCs of patients with cancer, we next performed Gene Ontology (GO) enrichment analysis to determine whether ER stress-related genes (GO: Response to Endoplasmic Stress) are differentially activated in ENL MDSC versus RR MDSC-like cells. Enrichment analysis was performed by investigating the overlap in ER stress-related genes ([Table S1](#mmc2){ref-type="supplementary-material"}, List of Endoplasmic Stress genes related to [Figure 2](#fig2){ref-type="fig"}) between the different leprosy datasets using the hypergeometric distribution to control for differences in the overall number of differentially expressed genes ([@bib41]). Indeed, we found a significant \>2-fold enrichment of ER stress-related genes in MDSC from patients with ENL over healthy controls, with RR MDSC-like cells displaying an intermediate level of ER stress that was not significant ([Figure 2](#fig2){ref-type="fig"}A).Figure 2ER Stress in Leprosy(A) ER stress response enrichment score of MDSC-like cells from patients with reversal reaction (RR) and healthy controls (HC) and MDSCs from patients with ENL was calculated using the hypergeometric distribution to control for differences in the overall number of differentially expressed genes. These tests determine if the degree of observed amount of enrichment is greater than expected. List of genes used is given in [Table S1](#mmc2){ref-type="supplementary-material"}. The left panel displays fold enrichment, the middle panel shows the significance of enrichment (1.3-p = 0.05, negative value represents under-enrichment), and the right panel shows fold enrichment for each patient (ENL n = 4, RR n = 5, HC n = 3, line represents mean ± SEM).(B and C) (B) Upregulation of ATF4, ATF6, IRE1, and XBP1 in HLA-DR^-^CD33^+^CD15^+^ (MDSC) isolated from ENL and RR blood (quantitative RT-PCR) ENL n = 6, RR n = 3, line represents mean ± SEM ∗p \< 0.05 Student's t test. (GSE129033) (C) ER stress response enrichment score of lesions from patients with reversal reaction (RR) and patients with ENL as in (A). The left panel displays fold enrichment, the middle panel shows significance of enrichment (1.3-p = 0.05), and the right panel shows fold enrichment for each patient (ENL n = 7, RR n = 7; line represents mean ± SEM [GSE43700](ncbi-geo:GSE43700){#intref0020}).(D and E) A T cell assay, as in [Figure 1](#fig1){ref-type="fig"}D, was performed, except in some cases MDSCs were treated with or without NAC or thapsigargin for 5 h prior to being irradiated and added to the T cell assay. (D) Effect of using 1 μM NAC---lowers ER stress, inhibits suppression (Proliferation Index; ENL n = 5, red are active ENL; line represents mean ± SEM, paired t test: p = 0.0033) or (E) thapsigargin (1 μM)---induces ER stress, augments suppression (Proliferation Index) on MDSCs from patients with RR (n = 7, red are active RR; line represents mean ± SEM, paired t test p = 0.0024).

To validate the transcriptomics findings, we performed real-time qPCR on additional MDSCs isolated from patients with ENL or RR reactions. The expression of master regulators of the ER stress response, including the transcription factors X-Box-binding protein 1 (XBP1), activating transcription factor 4 (ATF4), and its target gene ATF3, along with the cytoplasmic ER to nucleus signaling 1 (ERN1), were expressed 3- to 50-fold higher in HLA-DR^-^CD33^+^ cells isolated from patients with ENL compared with patients with RR ([Figure 2](#fig2){ref-type="fig"}B) ([@bib35]). These data suggest that the ER stress pathway contributed to suppressor activity of MDSCs.

To confirm whether ER stress may contribute to immunosuppression in lesions, we next examined if an ER stress signature existed in lesional biopsies of patients with leprosy with ENL or RR using the same enrichment analysis as above. This DNA microarray dataset was published previously ([@bib41]). We identified a 3-fold enrichment of ER stress genes in skin lesions from patients with ENL compared with patients with RR ([Figure 2](#fig2){ref-type="fig"}C). Taken together, the increased ER stress signature in both blood MDSCs and lesional skin of patients with ENL suggests a role for ER stress in the immune response of these patients.

Endoplasmic Reticulum Stress Regulates MDSC Suppressive Function in Patients with Leprosy {#sec2.4}
-----------------------------------------------------------------------------------------

We next tested whether ER stress regulates MDSC suppressor function in patients with leprosy. Similar to MDSCs from patients with cancer, the immunosuppressive activity of MDSCs from patients with ENL can be reversed by pretreatment with the free radical scavenger N-acetyl cysteine (NAC; [Figure 2](#fig2){ref-type="fig"}D) ([@bib3]). Alternatively, the induction of ER stress by thapsigargin (THG) in MDSC-like cells from patients with RR resulted in the ability of these cells to suppress T cell proliferation ([Figure 2](#fig2){ref-type="fig"}E). These data highlight the contribution of ER stress to MDSC suppressor function and support a role for ER stress in MDSC-induced immunosuppression in ENL reactions.

Presence of IL-10 Contributes to MDSC Suppressive Effects on T Cell Function in ENL {#sec2.5}
-----------------------------------------------------------------------------------

Since only MDSCs from ENL inhibited T cell proliferation consistently, we wanted to further explore how MDSCs may modulate immune responses. We treated MDSCs from patients across the clinical spectrum of leprosy with TLR2/1L (19-kD triacylated lipopeptide derived from mycobacteria) and measured cytokine production. Although the induction of most cytokines, including IL-6, IL-8, TNFα, and IL-1β, was similar between cells from patients with RR and ENL leprosy ([Figure S2](#mmc1){ref-type="supplementary-material"}), we found that IL-10 was more strongly induced in MDSCs from patients with ENL ([Figure 3](#fig3){ref-type="fig"}A). Since MDSCs have also been shown to regulate immunity through IL-10 production ([@bib2], [@bib29]) and IL-10 participates in the immunopathology of ENL ([@bib40]), we next tested whether IL-10 produced by MDSCs from patients with ENL contributed to T cell suppressor function. Antibody-mediated neutralization of IL-10 decreased the T cell suppressive function of MDSC isolated from patients with ENL when compared with isotype control antibody ([Figure 3](#fig3){ref-type="fig"}B). These data indicate that IL-10 produced by MDSCs from patients with ENL contributes to their suppressive activity.Figure 3MDSCs from Patients with ENL Produce More IL-10 owing to Increased ER Stress(A) HLADR^−^CD33^+^ cells were isolated from ENL, RR, or healthy individuals and stimulated with or without TLR2/1 ligand for 24 h. IL-10 production was measured by ELISA. Dashed line indicates the lowest limit of detection; all unstimulated cells were at this level (ENL n = 17, RR n = 6, HC n = 13; line represents mean of all samples Kruskal-Wallis p = 0.0059; Dunn\'s post hoc analysis ∗∗p \< 0.01 compared with healthy controls \[HC\]).(B) T cell suppression assay showing inhibition of suppression (Proliferation Index, a PI of 1 indicates no change) by MDSCs from patients with ENL treated with an anti-IL-10 neutralizing antibody (n = 6; paired t test p = 0.044).(C and D) (C) IL-10 production in MDSC-like cells treated with thapsigargin (to induce ER stress) for 5 h prior to a TLR2/1 ligand stimulation (n = 5; paired t test p = 0.045) (D) or MDSCs from patients with ENL treated with NAC for 5 h prior to stimulation with 19 kD (n = 5; paired t test p = 0.017).(E) T cell suppression assay showing inhibition of suppression (Proliferation Index) by MDSCs from patients with ENL if recombinant IFN-γ is added to the T cell assay (n = 6; paired t test p = 0.038).

To examine whether inducing ER stress in RR MDSC-like cells directly regulates IL-10 production we treated MDSC-like cells from patients with RR with thapsigargin or MDSCs from patients with ENL with NAC for 6 h prior to stimulation with 19 kD for 24 h. Although thapsigargin augmented IL-10 production ([Figure 3](#fig3){ref-type="fig"}C), the treatment of ENL MDSC with NAC inhibited IL-10 production ([Figure 3](#fig3){ref-type="fig"}D), confirming a regulatory role of ER stress in myeloid cell IL-10 production.

Enrichment of an IFN-γ Signature in MDSC-like Cells from Patients with RR {#sec2.6}
-------------------------------------------------------------------------

Since both ENL MDSC and RR MDSC-like cells both displayed some ER stress, a factor present in patients undergoing an RR may be able to overcome the ER-stress-dependent function to allow T cell activation. Using RNA-seq, we found only seven genes are increased significantly in RR MDSC-like cells compared with ENL MDSC. Three of these seven genes, AIM2, GBP4, and APOL3, are known IFN-γ inducible genes ([Table 2](#tbl2){ref-type="table"}) ([@bib36]). In addition, monocytes from patients with RR express an IFN-γ signature ([@bib41]). This led us to hypothesize that IFN-γ may be a factor that overcomes the suppressive effect of ER stress by MDSC. To test this hypothesis, we added IFN-γ to T cell suppression assays with MDSC from patients with ENL. Indeed, we found that the addition of recombinant IFN-γ restored T cell proliferation by MDSCs from patients with ENL ([Figure 3](#fig3){ref-type="fig"}E).

Discussion {#sec3}
==========

A better understanding of host-pathogen interactions is crucial for effectively treating chronic infections in humans. The model of leprosy is powerful in that infection of *M*. *leprae* leads to a spectrum of disease where some patients can control the bacterial infection and others cannot. Although the infiltration of myeloid cells from leprosy biopsy specimens has served as a key to histopathologic diagnosis of leprosy reactions, the role of these cells or other immune cells has not been evaluated in detail ([@bib6], [@bib23], [@bib34]). Herein, we identify an increase in immature myeloid cells displaying a cell surface phenotype of granulocytic MDSC (HLA-DR^-^CD33^+^CD15^+^) in the blood of patients with L-lep and ENL leprosy, both manifesting disseminated/progressive infection, and also in patients with RR , who are undergoing a cell-mediated immune response associated with the reduction of bacilli in lesions. However, only those MDSCs isolated from patients with L-lep and ENL, i.e., from the patient groups with weak cell-mediated immunity to *M*. *leprae*, were consistently able to suppress T cell function.

As there are distinct treatments for the different reactional states of leprosy, we considered the role of therapy in affecting MDSC suppressive function. All patients with active RR received systemic glucocorticoids, most commonly prednisone, whereas those with ENL received thalidomide ([Table 3](#tbl3){ref-type="table"}). Since glucocorticoids induce the release of myeloid cells into the blood from the bone marrow ([@bib26], [@bib42]), treatment with prednisone could explain the significant increase in MDSCs observed in patients with RR ([Figure 1](#fig1){ref-type="fig"}A). However, glucocorticoid treatment is a potent immunosuppressant that is known to enhance, rather than diminish, the suppressive function of MDSCs ([@bib42]). Since MDSCs from patients with RR demonstrated low suppressive activity, it is likely that glucocorticoid treatment of patients with RR may contribute to their increased numbers in circulation but not their lack of suppressor function. MDSCs from both patients with L-lep and ENL suppressed T cell responses *in vitro*, but only patients with ENL were treated with thalidomide, suggesting that thalidomide did not have a substantial effect on MDSC function.Table 3Leprosy Patient InformationClassificationThalidomide TreatmentPrednisone TreatmentAverage Age\# Of M\# Of FUnknown SexTotal \# of PatientsL-lep(2/11)(0/11)54 ± 17.291111ENL-inactive(3/20)(0/20)52.6 ± 14.1172120ENL-active(19/21)(0/21)43.2 ± 9.4161421RR-inactive(0/17)(1/17)46.5 ± 10.2152017RR-active(0/15)(13/15)49.1 ± 9.8131115T-lep(0/7)(0/7)60 ± 13.77007

Our data link ER stress to MDSC immunosuppressive activity across the spectrum of leprosy. An ER stress signature was recently identified as a major signature differentiating PMN-MDSCs from neutrophils in patients with cancer, finding OLR1 as a marker of immunosuppressive MDSCs when compared with neutrophils ([@bib4], [@bib3]). Herein, we extend these findings to human infectious disease by demonstrating increased OLR1 expression in immunosuppressive MDSCs from patients with ENL over those from non-suppressive cells from patients with RR by RNA-seq. Additionally, we found a significant enrichment of ER stress-related genes in both skin lesions and circulating MDSCs from patients with ENL. Quantitative real-time PCR from additional patients confirmed that regulators of ER stress were elevated in MDSCs from patients with ENL when compared with those from patients with RR. In summary, our data implicate ER stress in the immunosuppressive function of MDSCs from patients with ENL, which is linked to an ER stress signature at the site of disease. On the other hand, one study found that ER stress proteins are more highly expressed in lesions from patients with T-lep versus patients with L-lep ([@bib11]), suggesting that the overall pattern of ER stress at the site of infection may not fully correlate with MDSC suppressor activity.

Mechanistically, induction of ER stress, with thapsigargin, in previously non-suppressive MDSC-like cells from patients with RR resulted in increased suppressor function and IL-10 production, whereas blockade of ER stress or neutralization of IL-10 from previously suppressive MDSCs from patients with ENL resulted in diminished suppressor function and decreased IL-10 production. These findings suggest that clinical states known to be associated with a higher bacterial burden drive ER stress and increased IL-10 production enhancing the suppressive function of MDSCs. In fact, it was previously found that infection with *M*. *smegmatis* led to increased ER stress in a dose-dependent manner ([@bib14]). Additionally, infection of murine macrophage with Mtb H37Rv or H37Ra was shown to lead to increased ER stress and apoptosis and survival of bacteria, or not ([@bib17]) ([@bib18]). Although ER stress was increased in the groups of patients known to have greater numbers of bacilli in lesions, unfortunately, we do not have the bacterial burden information for all of the patients with leprosy studied to perform a direct correlation.

Alternatively, factors driving enhanced cell-mediated immunity, such as IFN-γ, as occurs in RR with augmentation of host defense resulting in the clinical change from the disseminated/progressive to the self-limited form of leprosy may disable MDSC function. The few genes differentially expressed in MDSC-like cells from patients with RR as compared with MDSCs from patients with ENL are predominantly IFN-γ signature genes, and in the presence of increased IFN-γ, normally suppressive MDSCs from patients with ENL displayed diminished suppressor activity ([Figure 3](#fig3){ref-type="fig"}E). Further work is needed to determine the effects of IFN-γ on MDSC function, but the finding that MDSC-like cells from patients with psoriasis also do not suppress T cell function ([@bib39]) and IFN-γ is present at high levels in patients with psoriasis ([@bib19]) suggest that IFN-γ may provide a signal that can overcome ER stress and disable MDSC function. There are a number of reports of *in vitro* models where IFN-γ has been demonstrated to induce ER stress and lead to decreased suppressive activity ([@bib7], [@bib31], [@bib44]); however, how tumor cells or cells with a persistent infection are affected by chronic ER stress *in vivo* is not understood. There is evidence that MDSCs from septic patients are not immunosuppressive until after their infection has cleared ([@bib12]) suggesting that MDSCs may behave differently in the context of cancer versus infection. Here we show that patients with ENL leprosy have MDSCs with an increased ER stress signature, which suppresses both T cell proliferation and IFN-γ production. If recombinant IFN-γ is added back into the assay, the same MDSCs are significantly less suppressive, suggesting a potential target for immunotherapy. IFN-γ is also increased in skin lesions of patients with RR where MDSC-like cells are not suppressive ([@bib41]). Whether IFN-γ directly prevents MDSC suppressive function, induces MDSC apoptosis ([@bib22]), or induces protective changes in the T cells that makes them resistant to suppression by MDSC in patients with RR requires further investigation.

Identifying the factors that disable ER stress in patients with leprosy may represent therapeutic targets to activate cell-mediated immunity to *M*. *leprae* in these patients. Additionally, treatment with factors that enhance ER stress may serve as an adjunct treatment in inflammatory skin disorders by increasing suppressive function of MDSC. Possible factors contributing to ER stress in patients with progressive leprosy could be increases in circulating IL-1β, IL-6, or type I interferon. All of these cytokines have been shown to increase ER stress in different cell types ([@bib25]) and are elevated in progressive forms of leprosy.

MDSCs utilize a variety of pathways to suppress T cell function including arginase, IL-4, iNOS, reactive oxygen species, and induction of other regulatory cell populations such as regulatory T cells ([@bib10], [@bib15], [@bib27]). IL-10 was shown to be an important mechanism for MDSC suppression of T cell function in a mouse model of ovarian cancer ([@bib9]). Although we have previously shown that IL-10 is elevated in L-lep lesions, we and others have shown that IL-10 is elevated in peripheral blood mononuclear cells (PBMCs) from patients with ENL ([@bib45]). Herein, we show that MDSCs from patients with ENL leprosy produce greater amounts of IL-10 in response to TLR2/1 ligand than MDSC-like cells from patients with RR leprosy, and their production of IL-10 contributes to their ability to suppress T cell function. Additionally, we have now linked increased ER stress to increased IL-10 production.

Taken together, our findings highlight the plasticity of immature myeloid cells in patients with leprosy. Suppression of T cell function by these cells may promote chronicity of infection and contribute to poor immunity to *M*. *leprae*. An ER stress pathway is activated during ENL and likely contributes to the overall immunosuppression seen. Overcoming this ER stress can subvert the suppressive effects of these cells. Cells of a similar phenotype have been reported in patients with atopic dermatitis, psoriasis, and melanoma. Although those cells from atopic dermatitis and melanoma possessed suppressive function against T cells, those from patients with psoriasis did not demonstrate suppressive function ([@bib32], [@bib38], [@bib39]). As opposed to our results showing that ER stress is linked to immunosuppression of T cell responses, ER stress in M1 macrophages has been shown to be required for optimal killing of intracellular pathogens ([@bib18], [@bib30]). Further work is needed to understand how the bacterial burden induces ER stress in patients with microbial infection and how it contributes to immune dysfunction. To our knowledge, leprosy is the first model in humans to demonstrate plasticity of MDSC function. Using this model to investigate myeloid cell development can lead to a better understanding of MDSCs, their function, and potentially therapies to prevent or exploit their function.

Limitations of the Study {#sec3.1}
------------------------

We acknowledge several limitations to the findings in this study. These include limited demographic and clinical information on each patient owing to samples being de-identified. We also do not know how long each patient has been on or off treatment nor do we have a bacillary index. Our established groups of patients with leprosy are based on a clinical and pathology diagnosis. In addition, because studies are performed on primary human cells, we rely on small molecule inhibitors rather than genetic perturbations for mechanistic studies.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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